Latest News on MXCT

Financial News Based On Company


Advertisement
Advertisement

Maxcyte CEO Masoud Maher buys $120,780 in company stock By Investing.com

https://ca.investing.com/news/stock-market-news/maxcyte-ceo-masoud-maher-buys-120780-in-company-stock-93CH-4968980
Maxcyte CEO Masoud Maher purchased 100,000 shares of the company's common stock for $120,780 on November 17, 2026. This insider buying aligns with an InvestingPro Tip about aggressive share buybacks and follows MaxCyte's strong third-quarter results, which saw a 49% revenue increase and narrowed loss per share, leading Stifel to reiterate a Buy rating. The stock is considered undervalued by InvestingPro, with a fair value of $1.31 against the current trading price of $1.25.

Form 4 MaxCyte Inc: Maher Masoud (Director, President and CEO) For: 17 November

https://ca.investing.com/news/stock-market-news/form-4-maxcyte-inc-maher-masoud-director-president-and-ceo-for-17-november-93CH-4968981
This article reports on a Form 4 filing for MaxCyte Inc, detailing insider transaction information related to Maher Masoud, who serves as a Director, President, and CEO. The filing pertains to activity on November 17. The article itself does not provide further details beyond the title and the fact of the filing.

At $1.21 a share or less, the CEO of MaxCyte (MXCT) bought company stock in multiple trades.

https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-8e5a450fd24d.html
MaxCyte, Inc. (MXCT) President and CEO Masoud Maher purchased 100,000 common shares of the company stock on November 17, 2026. The shares were acquired in multiple transactions at a weighted average price of $1.2078 per share, with individual prices ranging from $1.185 to $1.21. Following this transaction, Maher directly holds 575,000 common shares.

Rockville-Based MaxCyte Announces $151.8 Million Acquisition of Florida Biotech Company

https://mocoshow.com/2026/11/11/rockville-based-maxcyte-announces-151-8-million-acquisition-of-florida-biotech-company/
Rockville-based MaxCyte, Inc. is set to acquire Florida's Akron BioProducts LLC for approximately $151.8 million, a move expected to nearly double MaxCyte's revenue and expand its role in the cell therapy industry. The acquisition will enhance MaxCyte's presence across cell therapy manufacturing stages, increase recurring revenue, and accelerate its path to profitability. The deal involves $105 million in cash, 20.6 million shares of common stock, and $20 million in deferred payments, supported by a new credit facility of up to $75 million.

MaxCyte Inc (MXCT) (Q3 2026) Earnings Call Highlights: Revenue Surges 49% as Accron Acquisition ...

https://ca.finance.yahoo.com/news/maxcyte-inc-mxct-q3-2026-050925333.html
MaxCyte Inc (MXCT) reported a 49% year-over-year revenue increase in Q3 2026, reaching $10.2 million, with core revenue up 27%. The acquisition of Accron is projected to nearly double MaxCyte's revenue base, adding approximately $28 million in 2026 revenue and accelerating the company's path to profitability by diversifying its customer base and increasing recurring revenue. Despite remaining unprofitable with a year-to-date net loss of $18 million, the company maintains a strong balance sheet and updated its 2026 revenue guidance to at least $34.5 million.
Advertisement

MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base

https://finance.yahoo.com/healthcare/articles/maxcyte-acquire-akron-bio-expanding-110000071.html
MaxCyte, Inc. announced its definitive agreement to acquire Akron BioProducts LLC for $151.8 million, a move expected to nearly double MaxCyte's revenue base and accelerate its path to profitability. Akron Bio is a key supplier of GMP-grade reagents and ancillary materials for cell therapy manufacturing, which will expand MaxCyte's offerings across both viral and non-viral cell therapy workflows. The acquisition aims to enhance recurring revenue, commercial-stage exposure, and cross-selling opportunities, supporting five commercially approved therapies and over 100 clinical programs.

MaxCyte Q3 Revenue Rises 49% as 2026 Guidance Increases

https://grafa.com/en/news/united-states/maxcyte-q3-2026-revenue-rises-49-percent-raises-guidance-to-34-5-million
MaxCyte reported a 49% year-over-year increase in third-quarter 2026 revenue, reaching $10.2 million, and narrowed its net loss to $4.8 million. The company subsequently raised its full-year 2026 revenue guidance to at least $34.5 million, excluding the proposed Akron Bio acquisition. This updated forecast includes approximately $28 million in core revenue and anticipates about 15% core revenue growth in the second half of the year.

MaxCyte (MXCT) Q3 2026: Revenue Surges 49% as Akron BioProducts Deal Reshapes the Company

https://247wallst.com/cards/maxcyte-q3-2026-earnings-mxct-01m72t5gewtnr5c8sfzgk684f4
MaxCyte (MXCT) reported a significant Q3 2026 revenue beat, surging 49% year-over-year, alongside an announced acquisition of Akron BioProducts for $151.8 million. This strategic deal is expected to nearly double MaxCyte's revenue base, accelerate its path to profitability, and expand its presence in cell therapy development. The company also raised its full-year 2026 revenue guidance and projects reduced cash burn in 2027.

MXCT: MaxCyte Inc. filed SEC Form 8-K: Entry into a Material...

https://www.quantisnow.com/insight/maxcyte-inc-filed-sec-form-8-k-entry-into-a-material-6783095
MaxCyte Inc. (MXCT) filed an SEC Form 8-K announcing its agreement to acquire Akron BioProducts for $105.0 million in cash, 20.6 million shares, and $20.0 million in deferred payments. Concurrently, MaxCyte reported Q3 2026 revenue of $10.2 million and raised its full-year 2026 revenue guidance to at least $34.5 million. The acquisition is expected to nearly double MaxCyte's revenue but will result in share dilution and a significant cash outlay for existing shareholders.

Form 8K MaxCyte Inc For: 10 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-maxcyte-inc-for-10-november-93CH-4971666
This article from Investing.com announces the filing of a Form 8K by MaxCyte Inc. for November 10. The brief update indicates the release of this financial document, which typically reports unscheduled material events or corporate changes important to shareholders. No further details are provided within the article about the contents of the Form 8K.
Advertisement

MaxCyte to Acquire Akron Bio for $151.8 Million, Secures $75 Million Credit Facility

https://www.citybiz.co/article/931644/maxcyte-to-acquire-akron-bio-for-151-8-million-secures-75-million-credit-facility/
MaxCyte Inc. has agreed to acquire Akron BioProducts LLC for $151.8 million in a mix of cash, stock, and deferred payments, aiming to expand its cell-engineering technology business into reagents and materials for cell therapy manufacturing. This acquisition is projected to nearly double MaxCyte's revenue, accelerate its path to profitability, and broaden its reach in both viral and non-viral cell therapy markets. To finance the acquisition and support operations, MaxCyte also secured a $75 million credit facility from MidCap Financial.

MaxCyte to buy Akron Bio for $152M to double its revenue base

https://app.dealroom.co/news/note/maxcyte-to-buy-akron-bio-for-152m-to-double-its-revenue-base
MaxCyte has agreed to acquire Akron BioProducts for $151.8 million, a move expected to nearly double MaxCyte's revenue base and extend its reach into cell-therapy manufacturing. The deal, comprising cash, stock, and deferred payments, aims to accelerate MaxCyte's path to profitability by expanding its recurring revenue and commercial-stage exposure. This acquisition reflects the ongoing consolidation and reshaping of cell-therapy manufacturing capacity within the industry.

MaxCyte to Acquire Akron Bio, Expanding its Offerings

https://www.globenewswire.com/de/news-release/2026/11/10/3399272/0/en/maxcyte-to-acquire-akron-bio-expanding-its-offerings-across-cell-therapy-manufacturing-and-expecting-to-nearly-double-revenue-base.html
MaxCyte, a cell-engineering company, announced its acquisition of Akron BioProducts for $151.8 million. This acquisition is expected to nearly double MaxCyte's revenue base, expand its presence across the cell therapy manufacturing workflow, and accelerate its path to profitability by adding recurring consumables revenue and commercial-stage exposure. Akron Bio, a leading supplier of GMP-grade reagents, is projected to generate approximately $28 million in revenue and $7-8 million in EBITDA in 2026.

12 Health Care Stocks Moving In Monday's Pre-Market Session

https://www.benzinga.com/trading-ideas/movers/26/11/63026973/12-health-care-stocks-moving-monday-s-pre-market-session
This article lists 12 healthcare stocks that experienced significant movement in Monday's pre-market session. Six stocks saw gains, with MaxCyte (NASDAQ: MXCT) and Vir Biotechnology (NASDAQ: VIR) leading the increases, while another six stocks, including Zura Bio (NASDAQ: ZURA) and Faeth Therapeutics (NASDAQ: FTH), experienced declines. The article provides the percentage change, current stock price, and market capitalization for each company mentioned.

Liontrust Investment Partners LLP Trims MaxCyte Inc (MXCT) Stake -- Shares Trade 46% Below GF Value

https://www.gurufocus.com/news/9182640/liontrust-investment-partners-llp-trims-maxcyte-inc-mxct-stake-shares-trade-46-below-gf-value
Liontrust Investment Partners LLP has reduced its stake in MaxCyte Inc (MXCT) by selling 112,919 shares. Although the stock trades at a significant discount to its GF Value, GuruFocus flags it as a "Possible Value Trap" due to weak profitability and negative growth trends. The transaction reflects the firm's cautious approach to a loss-making life sciences company despite the apparent discount.
Advertisement

MaxCyte, Inc. (MYE0.F) Seasonal returns chart

https://uk.finance.yahoo.com/quote/MYE0.F/seasonality/
This article provides a seasonal returns chart for MaxCyte, Inc. (MYE0.F), displaying its average monthly price return between 2021 and 2026. The information is presented within a Yahoo Finance context, showing current stock performance and related market data.

Liontrust Investment Partners Discloses 4.9% Stake in MAXCYTE, INC.

https://www.tradingview.com/news/tradingview:8dc2be0a2d8e1:0-liontrust-investment-partners-discloses-4-9-stake-in-maxcyte-inc/
Liontrust Investment Partners LLP has disclosed a 4.9235% stake in MAXCYTE, INC., totaling 5,081,403 shares as of October 30, 2026. The firm filed its Schedule 13D on November 2, detailing recent share purchases and sales, including a sale of 112,919 shares and a combined purchase of 356,946 shares in October. The filing indicates the stake is for investment purposes and does not suggest a campaign to change the company.

A MaxCyte (MXCT) shareholder sold 112,919 shares on October 30 and reported its ownership stake.

https://www.stocktitan.net/sec-filings/MXCT/schedule-13d-maxcyte-inc-major-shareholder-acquisition-5-2b6f9bc83cb0.html
Liontrust Investment Partners LLP reported beneficial ownership of 5,081,403 shares, or 4.9235% of MaxCyte, Inc. (MXCT), with sole voting and dispositive power. The firm disclosed a sale of 112,919 shares on October 30, 2026, and multiple purchases on October 14, 2026. Although the filing heading suggests an acquisition above 5%, Liontrust's reported stake is just below this threshold.

MaxCyte (MXCT) Stock Forecast & Analyst Ratings

https://www.moomoo.com/stock/MXCT-US/forecast?chain_id=Name1K9-3FXPhg.1le2eo0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FIBKR-US%22%7D
This article provides a stock forecast and analyst ratings for MaxCyte (MXCT). It includes details on recent analyst actions and gives insights into the company's potential future performance based on expert opinions.

MaxCyte Inc. (MXCT) Stock Price | Live Quotes & Charts | NASDAQ

https://www.timothysykes.com/quote/MXCT/
This NASDAQ page provides live quotes and charts for MaxCyte Inc. (MXCT), showing its current stock price, recent change, and percentage decrease. It also includes sections for analyst ratings, indicating no current data, and earnings information, which is also unavailable. The page emphasizes that prices are delayed and encourages users to get real-time quotes elsewhere.
Advertisement

MaxCyte to Participate in Three Upcoming Investor Conferences

https://www.manilatimes.net/2026/10/28/tmt-newswire/globenewswire/maxcyte-to-participate-in-three-upcoming-investor-conferences/2456090/amp
MaxCyte, Inc. announced its management will participate in three upcoming investor conferences: the Stifel 2026 Healthcare Conference, the 17th Annual Craig-Hallum Alpha Select Conference, and the Stephens Annual Investment Conference. Webcasts of these events will be available on the company's investor relations website. MaxCyte is a leading cell-engineering company focused on advancing next-generation cell therapeutics.

MaxCyte to Participate in Three Upcoming Investor Conferences

https://www.manilatimes.net/2026/10/28/tmt-newswire/globenewswire/maxcyte-to-participate-in-three-upcoming-investor-conferences/2456090
MaxCyte, Inc. (NASDAQ: MXCT) announced its management will participate in three upcoming investor conferences in November 2026, including the Stifel 2026 Healthcare Conference, the 17th Annual Craig-Hallum Alpha Select Conference, and the Stephens Annual Investment Conference. Live and archived webcasts of the events will be available on the company's investor relations website. MaxCyte is a leading cell-engineering company focused on advancing next-generation cell therapeutics.

MaxCyte to Participate in Three Upcoming Investor Conferences

https://www.moomoo.com/news/post/1002653607/maxcyte-to-participate-in-three-upcoming-investor-conferences
MaxCyte, a company providing cell-engineering platform technologies, announced its participation in three upcoming investor conferences: the Stifel Healthcare Conference, the Citi BioPharma Conference, and the Piper Sandler Healthcare Conference. Management will engage in one-on-one meetings with investors at all three events.

MaxCyte Inc. (MXCT) Stock Price | Live Quotes & Charts | NASDAQ

https://timothysykes.com/quote/MXCT/
This NASDAQ page provides live quotes and charts for MaxCyte Inc. (MXCT), showing its current stock price, daily change, and percentage change. It also includes sections for analyst ratings and earnings information, though specific data for these categories is currently unavailable. The page features a disclaimer regarding the risks of stock trading, particularly penny stocks and day trading.

Genomics for CRISPR: An introduction to genomic safety assessment

https://www.news-medical.net/health/Genomics-for-CRISPR-An-introduction-to-genomic-safety-assessment.aspx
This article introduces genomic safety assessment in CRISPR therapies, highlighting the critical need to identify and mitigate off-target editing that can lead to adverse cellular outcomes. It details MaxCyte's SeQure portfolio, including tools like Guide-Profiler™, ONE-seq™, CHANGE-seq™, and SAFER™, which are designed to provide regulatory-aligned, comprehensive nomination and confirmation of off-target sites and structural rearrangements for both nucleases and base editors. The piece underscores the importance of orthogonal approaches and sensitive detection methods to ensure the safety and regulatory compliance of CRISPR-based treatments throughout their development lifecycle.
Advertisement

MaxCyte, Inc. Estimates – NASDAQ:MXCT

https://www.tradingview.com/symbols/NASDAQ-MXCT/financials-estimates/
This article provides an overview of MaxCyte, Inc. (NASDAQ:MXCT) financials and analyst estimates available on TradingView. It highlights sections for exploring reported financial data across income statements, balance sheets, cash flow, and valuation metrics, allowing users to compare actual results with various estimates and visualize trends.

Genome Safety Webinar Series: Regulatory Expectations, Practical Wor

https://crisprmedicinenews.com/cmn-webinars/new-webinar-template/maxcyter-presents-genome-safety-webinar-series-regulatory-expectations-practical-workflows-and-expert-insights/
MaxCyte is hosting a three-session webinar series on genome safety, focusing on regulatory expectations, practical workflows, and expert insights for gene editing technologies. The series will cover the history and regulatory landscape of genome safety, assay design and data integration for IND-enabling development, and feature a panel discussion with leaders in therapeutic development. It aims to help participants strengthen their safety assessment strategies and make informed development decisions.

SeQure™ Genome Safety Webinar Series: Regulatory Expectations, Practical Wor

https://crisprmedicinenews.com/cmn-webinars/new-webinar-template/maxcyter-presents-sequretm-genome-safety-webinar-series-regulatory-expectations-practical-workflows-and-expert-insights/
MaxCyte is hosting a three-part "SeQure™ Genome Safety Webinar Series" to address challenges in genomic safety assessment for gene editing therapies. The series will cover the history of genome safety and regulatory requirements, IND roadmap for genome safety, and expert perspectives on measurement strategies and decision-making. These webinars aim to help developers translate genomic-safety measurements into confident development decisions by exploring evolving FDA expectations and practical workflows.

MaxCyte consensus sets USD 6.00 target for MaxCyte stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/maxcyte-consensus-sets-usd-6-00-target-for-maxcyte-stock/70376979
A six-analyst consensus has set a 12-month target of USD 6.00 for MaxCyte stock, significantly above its current Nasdaq price. The company reported preliminary core business revenue of USD 8.10 million for Q3 2026, a 26% increase year-over-year, and raised its full-year revenue guidance to USD 34.00 million. MaxCyte is scheduled to release its full third-quarter results on November 10, 2026.

November 10, 2026 results are next for MaxCyte stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/november-10-2026-results-are-next-for-maxcyte-stock/70331573
MaxCyte's earnings call is scheduled for November 10, 2026, where the full third-quarter results, including royalty revenue, will be released. The company reported preliminary core business revenue of USD 8.10 million for Q3 2026, a 26% increase year-over-year. As of October 15, 2026, MaxCyte's stock was trading at EUR 1.15 on Lang & Schwarz and USD 1.29 on Nasdaq, with a market capitalization of USD 133.3 million.
Advertisement

Liontrust Investment Partners Discloses Investment at MaxCyte with 5.03% Stake

https://www.tradingview.com/news/tradingview:1784d7a4e6bf2:0-liontrust-investment-partners-discloses-investment-at-maxcyte-with-5-03-stake/
Liontrust Investment Partners LLP has disclosed a 5.03% beneficial stake in MAXCYTE, INC. common stock, as detailed in a Schedule 13D filing on October 15, 2026. This filing follows a series of September sales and subsequent purchases on October 14, which pushed Liontrust's ownership just above the 5% threshold requiring the active 13D. The UK-based investment manager did not outline any plans for strategic changes or board seats at MaxCyte, indicating routine share transactions.

An investor reports over 5% of MaxCyte (MXCT) after October 14 share purchases.

https://www.stocktitan.net/sec-filings/MXCT/schedule-13d-maxcyte-inc-major-shareholder-acquisition-5-6ecd67ef50df.html
Liontrust Investment Partners LLP has reported acquiring over 5% beneficial ownership in MaxCyte, Inc. (MXCT), totaling 5,194,322 shares, or 5.033% of the class. This filing follows several sales in September and early October, with significant share purchases occurring on October 14, 2026, at $1.26072563 per share. The acquisition indicates a potential intent to influence control as per the Schedule 13D filing requirements.

12 Health Care Stocks Moving In Wednesday's Intraday Session

https://www.benzinga.com/trading-ideas/movers/26/10/62363232/12-health-care-stocks-moving-wednesday-s-intraday-session
This article details 12 healthcare stocks experiencing significant movement during Wednesday's intraday session. It lists six top gainers, including MaxCyte and Liquidia, with their respective stock price increases and market caps. The article also identifies six top losers, such as CDT Equity and Biomea Fusion, noting their stock declines and market valuations.

MaxCyte stock surges 25% on raised 2026 revenue guidance

https://www.investing.com/news/stock-market-news/maxcyte-stock-surges-25-on-raised-2026-revenue-guidance-4949732
MaxCyte Inc. (NASDAQ:MXCT) shares surged 25% after the cell-engineering company raised its full-year 2026 revenue guidance. This increase follows strong third-quarter results, with core business revenue up 26% year-over-year and exceeding analyst estimates. The company anticipates approximately $34 million in total revenue for 2026, driven by accelerated instrument purchasing and growth in its Strategic Platform License Program.

Press Release: MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

https://www.moomoo.com/news/post/1001169626/press-release-maxcyte-reports-preliminary-third-quarter-2026-revenue-and
MaxCyte has announced preliminary third-quarter 2026 revenue of approximately $10.0 million, which represents a 25% increase compared to the third quarter of 2025. Following this strong performance, the company has raised its full-year 2026 revenue guidance to a range of $39.0 million to $40.0 million, up from its previous guidance of $38.0 million to $39.0 million. This update will be further discussed during their upcoming investor webcast on November 10, 2026.
Advertisement

MaxCyte MXCT Hires Danaher Dealmaker To Drive Growth

https://stockstotrade.com/news/maxcyte-inc-mxct-news-2026_10_14/
MaxCyte (MXCT) has appointed Sidharth Kapileshwar, a former Danaher executive, as Chief Corporate Development Officer to accelerate its growth strategy, M&A, and platform expansion. This move signals MaxCyte's intent to be more aggressive in partnerships and deals, moving beyond slow organic growth. While the stock has recently traded lower, this leadership change could be an early indicator for traders looking for future strategic developments and a potential re-rating of the company.

MaxCyte Raises 2026 Revenue Guidance to About $34 Million

https://www.quiverquant.com/news/MaxCyte+Raises+2026+Revenue+Guidance+to+About+%2434+Million
MaxCyte (MXCT) reported preliminary third-quarter 2026 core business revenue of approximately $8.1 million, a 26% increase from the previous year, and over $1.0 million in Strategic Platform License program-related revenue. Consequently, the company raised its full-year 2026 revenue guidance to about $34 million, up from the previous range of $30 million to $32 million. MaxCyte plans to release its full third-quarter financial results on November 10, 2026.

MaxCyte raises 2026 revenue guidance after strong Q3 results

https://www.streetinsider.com/Corporate+News/MaxCyte+raises+2026+revenue+guidance+after+strong+Q3+results/27184130.html
MaxCyte (NASDAQ: MXCT) reported strong preliminary third-quarter 2026 results, with core business revenue increasing 26% year-over-year to $8.1 million and SPL Program-related revenue exceeding $1.0 million. Following this performance, the company raised its full-year 2026 revenue guidance to approximately $34 million, up from $30 million to $32 million previously. The revised guidance reflects accelerated instrument purchasing and confidence in double-digit growth.

MaxCyte reports Q3 preliminary revenue $9.1M and raises 2026 revenue guidance to ~$34M

https://www.tradingview.com/news/tradingview:868d6cef11080:0-maxcyte-reports-q3-preliminary-revenue-9-1m-and-raises-2026-revenue-guidance-to-34m/
MaxCyte reported preliminary third-quarter 2026 revenue of $9.1 million, including $8.1 million from core business and over $1.0 million from Strategic Platform License (SPL) Program-related revenue. The company raised its full-year 2026 revenue guidance to approximately $34 million, up from the previous guidance of $30–$32 million. This increase is attributed to strong Q3 core business performance and advancing SPL partnerships, with full financial results to be released on November 10, 2026.

MaxCyte, Inc. (MXCT) options chain

https://uk.finance.yahoo.com/quote/MXCT/options/?date=1792108800&straddle=false&type=all
This article provides the options chain for MaxCyte, Inc. (MXCT), detailing both call and put options. It includes data such as strike price, last price, bid, ask, volume, open interest, and implied volatility for options expiring on October 16, 2026. The stock was trading at $1.0100, down 0.98%, at market close on October 9.
Advertisement

MaxCyte stock fell 3.67 percent on October 7

https://www.ad-hoc-news.de/boerse/news/nebenwerte/maxcyte-stock-fell-3-67-percent-on-october-7/70261026
MaxCyte's stock (MXCT) dropped 3.67% on October 7, trading at USD 1.050 on Nasdaq. The company reported a 15% year-over-year revenue decrease in Q2 2026, totaling USD 7.271 million, and maintained its fiscal 2026 revenue guidance at USD 30 million to USD 32 million. Analysts have a "Strong Buy" consensus with an average 12-month price target significantly above its current trading price.

MaxCyte stock gained 0.9 percent as revenue fell 15 percent

https://www.ad-hoc-news.de/boerse/news/nebenwerte/maxcyte-stock-gained-0-9-percent-as-revenue-fell-15-percent/70248600
MaxCyte stock saw a 0.9 percent gain to USD 1.08 on October 6, 2026, despite a 15 percent drop in second-quarter revenue to USD 7.3 million compared to the previous year. The company maintained its full-year revenue guidance of USD 30 million to USD 32 million, projecting a strong recovery in the second half of 2026. Analysts hold a "Strong Buy" consensus with an average 12-month target price of USD 4.108, significantly higher than the current stock price, indicating a wide valuation gap.

MaxCyte stock fell 1.83 percent as Q2 revenue dropped 15 percent

https://www.ad-hoc-news.de/boerse/news/corporate-news/maxcyte-stock-fell-1-83-percent-as-q2-revenue-dropped-15-percent/70223638
MaxCyte's stock declined by 1.83 percent after the company reported a 15 percent drop in Q2 revenue, bringing in $7.3 million. Despite the revenue decrease, management maintained its 2026 guidance at $30 million to $32 million, anticipating low single-digit growth in the second half of the year. The company's stock traded within a wide 52-week range of $0.64 to $1.87, and analysts currently hold a "Hold" consensus with a target price significantly above the current market price.

MaxCyte (MXCT) Stock Analysis Report | Financials & Insights

https://es.benzinga.com/quote/MXCT/report
This report provides a financial analysis of MaxCyte (MXCT), a life sciences company focused on cell engineering technology. It covers the company's financial health, past performance, and detailed income statements, balance sheets, and cash flow statements for the past four years. The analysis includes key financial indicators like operating margin, quick ratio, and debt-to-equity, along with a comparison to its peers.

MaxCyte appoints Sidharth Kapileshwar as chief corporate officer

https://www.investing.com/news/company-news/maxcyte-appoints-sidharth-kapileshwar-as-chief-corporate-officer-93CH-4912931
MaxCyte Inc. has appointed Sidharth Kapileshwar as its Chief Corporate Development Officer. Kapileshwar brings nearly 25 years of experience in corporate development, strategy, innovation, and M&A leadership from companies like Danaher Corporation, GE Healthcare, and Beckman Coulter. MaxCyte's CEO, Maher Masoud, highlighted Kapileshwar's proven ability to build and scale corporate development functions within major healthcare organizations.
Advertisement

MaxCyte stock slips 4.03 percent as new chief arrives

https://www.ad-hoc-news.de/boerse/news/nebenwerte/maxcyte-stock-slips-4-03-percent-as-new-chief-arrives/70177307
MaxCyte stock dropped 4.03% following the appointment of a new chief corporate development officer. Despite a 15% fall in Q2 2026 revenue to $7.3 million, the biotechnology company maintained its full-year revenue guidance of $30 million to $32 million. The new hire, Sidharth Kapileshwar, is expected to help broaden the company's cell engineering platform partnerships, as MaxCyte continues to balance cost reductions with weaker licensing and instrument revenue.

MaxCyte appoints Sidharth Kapileshwar as chief corporate officer By Investing.com

https://za.investing.com/news/stock-market-news/maxcyte-appoints-sidharth-kapileshwar-as-chief-corporate-officer-93CH-4474583
MaxCyte, Inc. (NASDAQ:MXCT) has appointed Sidharth Kapileshwar as its new Chief Corporate Development Officer. Kapileshwar brings 25 years of experience in corporate development, strategy, innovation, and M&A from companies like Danaher, GE Healthcare, and Beckman Coulter. MaxCyte's President and CEO, Maher Masoud, highlighted Kapileshwar's proven track record in building corporate development functions within major healthcare companies.

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

https://www.stocktitan.net/news/MXCT/max-cyte-appoints-sidharth-kapileshwar-as-chief-corporate-i6t8hdfus1vk.html
MaxCyte (MXCT) has appointed Sidharth Kapileshwar as Chief Corporate Development Officer, bringing nearly 25 years of experience in corporate development, strategy, innovation, and M&A from major life sciences companies like Danaher, GE Healthcare, and Beckman Coulter. Kapileshwar's expertise is expected to support MaxCyte's next growth phase, particularly in advancing its flow electroporation technology for cell and gene therapies. His appointment also included inducement awards of stock options and restricted units.

MaxCyte appoints Sidharth Kapileshwar as chief corporate officer By Investing.com

https://ng.investing.com/news/stock-market-news/maxcyte-appoints-sidharth-kapileshwar-as-chief-corporate-officer-93CH-2705982
MaxCyte, Inc. has announced the appointment of Sidharth Kapileshwar as Chief Corporate Development Officer. Kapileshwar brings nearly 25 years of experience in corporate development, strategy, innovation, and M&A from companies like Danaher, GE Healthcare, Beckman Coulter, and Halma plc. MaxCyte's President and CEO, Maher Masoud, highlighted Kapileshwar's proven track record in building and scaling corporate development functions within major healthcare companies.

MaxCyte Names Sidharth Kapileshwar Chief Corporate Development Officer

https://www.citybiz.co/article/907810/maxcyte-names-sidharth-kapileshwar-chief-corporate-development-officer/
MaxCyte Inc. has appointed Sidharth Kapileshwar as its Chief Corporate Development Officer, bringing nearly 25 years of experience in strategy, M&A, and innovation. Kapileshwar, who previously held leadership roles at Danaher Corp., GE Healthcare, Beckman Coulter, and Halma plc, will help guide MaxCyte's growth in the cell and gene therapy market. His expertise is expected to be crucial as the company continues to develop its cell-engineering technologies, including its Flow Electroporation technology and SeQure DX gene-editing risk assessment services.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement